Scientists say data on the coronavirus disease 2019 (COVID-19) treatment convalescent plasma may be misrepresented; Anthony Fauci, MD, warned that distributing a COVID-19 vaccine without testing in large trials could affect other vaccines; remdesivir was shown to have little effect in patients hospitalized with COVID-19.
After being granted emergency use authorization (EUA) by the FDA, data on the coronavirus disease 2019 (COVID-19) treatment convalescent plasma is being challenged by scientists nationwide as they say it misrepresents its potential efficacy among the general population. Reported by The New York Times, President Trump and 2 of his top officials said that the treatment had reduced deaths by 35%. However, scientists say that data was based on a small subgroup of hospitalized patients with COVID-19 who were under 80 years old, not on ventilators, and received the treatment within 3 days of diagnosis.
Reported by Reuters, the nation’s top infectious disease expert Anthony Fauci, MD, warned that distributing a COVID-19 vaccine under EUA guidelines, without assessing its safety and efficacy in large trials, could lead to an adverse effect on the testing of other vaccines. Noting risks of this strategy, Fauci said that prematurely releasing a vaccine would make it difficult, if not impossible, for other vaccines to enroll people in their trial. These comments come as President Trump claimed, without evidence, that “deep state” elements at the FDA were delaying progress to harm his November election bid.
According to open-label trial findings published last week in JAMA, the antiviral drug remdesivir was shown to have little effect in patients hospitalized with COVID-19 in 105 hospitals across the United States, Europe, and Asia. Reported by CIDRAP, there were no significant differences in duration of supplemental oxygen or hospitalization between the intervention group given remdesivir and the control group given standard care. However, a separate small study published in the Journal of Antimicrobial Chemotherapy Monday suggests the therapy may benefit patients with COVID-19 who are receiving mechanical ventilation.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Real-World Data Show Poor Outcomes Among Patients With ACS and Blood Cancers
December 8th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More